MARKET

INCY

INCY

Incyte Corp
NASDAQ
65.87
+0.50
+0.76%
After Hours: 65.83 -0.04 -0.06% 19:38 07/19 EDT
OPEN
65.54
PREV CLOSE
65.37
HIGH
66.10
LOW
64.98
VOLUME
1.56M
TURNOVER
0
52 WEEK HIGH
67.37
52 WEEK LOW
50.27
MARKET CAP
14.79B
P/E (TTM)
20.00
1D
5D
1M
3M
1Y
5Y
1D
Incyte Corp: Statement of changes in beneficial ownership of securities
Press release · 2d ago
Most shorted S&P 500 stocks in June
American Airlines Group (AAL), Albemarle (ALB) and Charter Communications (CHTR) lead the list of most shorted S&P 500 stocks as a percentage of float in June. Short interest in the U.S. Carrier increased by 10.14% since mid-June.
Seeking Alpha · 2d ago
Incyte, Moderna among most shorted S&P 500 healthcare stocks in June
Seeking Alpha · 3d ago
Are Strong Financial Prospects The Force That Is Driving The Momentum In Incyte Corporation's NASDAQ:INCY) Stock?
Incyte's (NASDAQ:INCY) ROE is 14% higher than the industry average. Incyte has a net income growth of 25% over the past five years. The company has a return on equity of 14% and is reinvesting heavily into its business. We look at the company's profitability to assess its ability to generate profits. In cyte's industry average is 16%.
Simply Wall St · 3d ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
NASDAQ · 3d ago
U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. BlackRock, Goldman Sachs and Netflix revise their ratings and targets on Tuesday. Broadcom, Amazon.com and American Tower among companies with new targets. Some of the companies have announced stock splits.
Reuters · 3d ago
INCYTE CORP <INCY.O>: JP MORGAN CUTS TARGET PRICE TO $59 FROM $60
Reuters · 4d ago
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
NASDAQ · 4d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.